 | Up a level |
Stathis, Anastasios; Pirosa, Maria Cristina; Orsucci, Lorella; Feugier, Pierre; Tani, Monica; Ghesquières, Hervé; Musuraca, Gerardo; Rossi, Francesca Gaia; Merli, Francesco; Guièze, Romain; Gyan, Emmanuel; Gini, Guido; Marino, Dario; Gressin, Remy; Morschhauser, Franck; Cavallo, Federica; Palombi, Francesca; Conconi, Annarita; Tessoulin, Benoît; Tilly, Hervé; ... (2024). IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. Haematologica - the hematology journal, 109(8), pp. 2564-2573. Ferrata-Storti Foundation 10.3324/haematol.2023.283918
Dreyling, Martin; Doorduijn, Jeanette; Giné, Eva; Jerkeman, Mats; Walewski, Jan; Hutchings, Martin; Mey, Ulrich; Riise, Jon; Trneny, Marek; Vergote, Vibeke; Shpilberg, Ofer; Gomes da Silva, Maria; Leppä, Sirpa; Jiang, Linmiao; Stilgenbauer, Stephan; Kerkhoff, Andrea; Jachimowicz, Ron D; Celli, Melania; Hess, Georg; Arcaini, Luca; ... (2024). Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. The lancet, 403(10441), pp. 2293-2306. Elsevier 10.1016/S0140-6736(24)00184-3
